Systemic inflammatory response and nutritional biomarkers as predictors of nivolumab efficacy for gastric cancer

Namikawa, Tsutomu; Yokota, Keiichiro; Tanioka, Nobuhisa; Fukudome, Ian; Iwabu, Jun; Munekage, Masaya; Uemura, Sunao; Maeda, Hiromichi; Kitagawa, Hiroyuki; Kobayashi, Mariko; Hanazaki, Kazuhiro

doi:10.1007/s00595-020-02048-w

Cited by 39 publications

(63 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…(A) median overall survival was 6.77 (95% confidence interval of 5.33-9.30) months, (B) median progression-free survival was 2.53 (95% confidence interval of 2.10-2.83) months and albumin levels, is independently associated with survival in patients with GC treated with nivolumab; the present study findings are consistent with those of this previous study. 19 Lymphocytes play a critical role in the host immune response and may suppress cancer progression. 20 Peripheral PD-1 positive CD4 T-lymphocyte count has been associated with PFS in non-small cell lung cancer patients treated with immune checkpoint inhibitors.…”

Section: Discussionmentioning

confidence: 99%

The new prognostic score for unresectable or recurrent gastric cancer treated with nivolumab: A multi‐institutional cohort study

Sato

Oshima

et al. 2021

Annals of Gastroent Surgery

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

The new prognostic score for unresectable or recurrent gastric cancer treated with nivolumab: A multi‐institutional cohort study

Sato

Oshima

et al. 2021

Annals of Gastroent Surgery

View full text Add to dashboard Cite

show abstract

“…Only a single study besides the present one examined the association between PNI and survival in GC patients undergoing nivolumab monotherapy. PNI after administering nivolumab, and not PNI before nivolumab therapy, was a risk factor for prognosis (35). In this study, we investigated whether PNI administered before nivolumab therapy could be a biomarker for treatment response and demonstrated that the high-PNI group had worse outcomes than the low-PNI group.…”

Section: Discussionmentioning

confidence: 98%

Effect of Prognostic Nutrition Index in Gastric or Gastro-oesophageal Junction Cancer Patients Undergoing Nivolumab Monotherapy

Watanabe

Yamada

Komori

et al. 2021

In Vivo

View full text Add to dashboard Cite

Background/Aim: We hypothesised that the prognostic nutrition index (PNI) is useful for evaluating host immunity and response to immune checkpoint inhibitors. We investigated the effect of PNI on nivolumab monotherapy efficacy in advanced or recurrent gastric cancer (GC) or gastro-oesophageal junction cancer (GOC) patients. Patients and Methods: We retrospectively examined 110 patients, divided them into a high-PNI group and a low-PNI group, and compared treatment efficacy, adverse events (AEs), and survival between the groups. Results: Median overall survival (OS) was significantly longer in the high-PNI group than in the low-PNI group (205 vs. 109 days; p<0.001). Multivariate analysis revealed that low PNI was an independent risk factor for OS (hazard ratio=2.398; 95% confidence interval=1.384-4.154; p=0.002). The overall response rate and frequency of AEs were not significantly different between the groups. Conclusion: PNI could be a useful prognostic factor in GC or GOC patients undergoing nivolumab monotherapy.

show abstract

“…In recent years, the development of immune-related adverse events and systemic inflammatory were associated with clinical benefit for advanced gastric cancer patients receiving immune checkpoint inhibitors treatment has been demonstrated. 28,29 These studies suggest that SR may be a predictor of the effect or indicator of sensitivity of immune checkpoint inhibitors. However, an association of SR with PD-1 and PD-L1 was not observed in the present immunohistological studies.…”

Section: Discussionmentioning

confidence: 99%

Clinical significance of sarcoid‐like reaction in lymph nodes of gastric cancer patients

Itai

Ueda

Etoh

et al. 2021

Journal of Surgical Oncology

View full text Add to dashboard Cite

Background: Although granulomatous formation (sarcoid-like reaction [SR]) similar to sarcoidosis occasionally occurs in regional lymph nodes of malignant tumors, the pathological significance of SR is unknown. We aimed to elucidate the clinicopathological significance and prognostic relevance of SR in gastric cancer.Methods: We evaluated 391 patients who underwent curative gastrectomy for gastric cancer between 2007 and 2016 at our hospital. The patients were divided into two groups according to presence of SR in lymph nodes, and clinicopathological factors and prognosis were compared between the two groups.Results: SR was found in 67 (17.1%) of the 391 patients, and 332 (3.3%) of 10,149 lymph nodes examined. Regarding clinicopathological factors, SR-positive group showed significantly higher average age (p < 0.01) and numbers of differentiated tumors than SR-negative group (p < 0.05). Three-year overall survival rate in elderly patients aged ≥75 years was significantly more favorable in SR-positive group (n = 27, 85.2%) versus SR-negative group (n = 97, 63.4%) (p < 0.05). Immunohistochemical studies showed the predominant presence of CD68-positive macrophages for SR, with CD4/CD8-positive T cells and interleukin-10 also positive. Conclusion:The presence of SR in gastric cancer is frequent in elderly patients and might be a favorable indicator of prognosis. SR is suggested to reflect immune activation in the host.

show abstract

Systemic inflammatory response and nutritional biomarkers as predictors of nivolumab efficacy for gastric cancer

Cited by 39 publications

References 38 publications

The new prognostic score for unresectable or recurrent gastric cancer treated with nivolumab: A multi‐institutional cohort study

The new prognostic score for unresectable or recurrent gastric cancer treated with nivolumab: A multi‐institutional cohort study

Effect of Prognostic Nutrition Index in Gastric or Gastro-oesophageal Junction Cancer Patients Undergoing Nivolumab Monotherapy

Clinical significance of sarcoid‐like reaction in lymph nodes of gastric cancer patients

Contact Info

Product

Resources

About